NYMC Faculty Publications
Rituximab Pharmacokinetics in Children and Adolescents With De Novo Intermediate and Advanced Mature B-cell Lymphoma/Leukaemia: A Children's Oncology Group Report
Author Type(s)
Faculty
DOI
10.1111/bjh.12434
Journal Title
British Journal of Haematology
First Page
678
Last Page
683
Document Type
Article
Publication Date
9-1-2013
Department
Pediatrics
Abstract
The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.
Recommended Citation
Barth, M., Goldman, S., Smith, L., Perkins, S., Shiramizu, B., Gross, T., Harrison, L., Sanger, W., Geyer, M., Giulino-Roth, L., & Cairo, M. (2013). Rituximab Pharmacokinetics in Children and Adolescents With De Novo Intermediate and Advanced Mature B-cell Lymphoma/Leukaemia: A Children's Oncology Group Report. British Journal of Haematology, 162 (5), 678-683. https://doi.org/10.1111/bjh.12434
